SAN FRANCISCO (KGO) -- The Centers for Disease Control and Prevention (CDC) released new data Friday indicating the Delta variant is twice as infectious as previously thought, and a recent analysis ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company’s Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) ...
Mirum Pharmaceuticals has entered a definitive agreement to acquire Bluejay Therapeutics — a deal that, if finalized, would add brelovitug, a phase 3-stage monoclonal antibody for chronic hepatitis ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the ...
LAS VEGAS, NEVADA -- A California couple says they were fully vaccinated, but still contracted COVID-19 while on vacation as experts say breakthrough cases are possible, especially with the delta ...
"HDV should not be managed as a uniform condition. Sex-related differences matter." — Loreta A. Kondili, MD, National Center for Global Health, Italian Institute of Health, Rome “HDV is the most ...
– Week 48 endpoint results from the SOLSTICE Phase 2 clinical study evaluating tobevibart alone or in combination with elebsiran for chronic hepatitis delta to be presented – Vir Biotechnology (VIR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results